Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma

详细信息    查看全文

• 作者：Girolamo Pelaia^a ; ^{pelaia@unicz.it" class="auth_mail" title="E-mail the corresponding author} ; Alessandro Vatrella^b ; Maria Teresa Busceti^a ; Francesco Fabiano^c ; Rosa Terracciano^d ; Maria Gabriella Matera^e ; Rosario Maselli^a
• 关键词：Budesonide ; Glucocorticoids ; Asthma
• 刊名：Pulmonary Pharmacology & Therapeutics
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：40
• 期：Complete
• 页码：15-21
• 全文大小：893 K

文摘

Inhaled glucocorticoids are the mainstay of asthma treatment. Indeed, such therapeutic agents effectively interfere with many pathogenic circuits underpinning asthma. Among these drugs, during the last decades budesonide has been probably the most used molecule in both experimental studies and clinical practice. Therefore, a large body of evidence clearly shows that budesonide, either alone or in combination with long-acting bronchodilators, provides a successful control of asthma in many patients ranging throughout the overall spectrum of disease severity. These excellent therapeutic properties of budesonide basically depend on its molecular mechanisms of action, capable of inhibiting within the airways the activity of multiple immune-inflammatory and structural cells involved in asthma pathobiology.